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W
e are two of the scientist 
members of the President’s 
Council on Bioethics. In late 
2001, we were invited by the President 
of the United States to serve on this 
Council. The Bioethics Council was 
appointed by the President to “monitor 
stem-cell research, to recommend 
appropriate guidelines and regulations, 
and to consider all of the medical and 
ethical ramiﬁ  cations of biomedical 
innovation.... This council will keep 
us apprised of new developments and 
give our nation a forum to continue to 
discuss and evaluate these important 
issues.”
This was a difﬁ  cult invitation 
to accept. On the one hand, the 
President’s views on the use of human 
embryonic stem cell research and 
somatic cell nuclear transfer techniques 
were well-known and in conﬂ  ict with 
our own beliefs about the costs and 
beneﬁ  ts of the use of progressive 
technologies to advance biomedical 
research. On the other hand, we were 
grateful that the President, despite his 
views in opposition to these therapies, 
was willing to invite serious biomedical 
scientists to help formulate advice to 
him—and ultimately to contribute to 
the development of national policy—
on these critically important advances.
We knew that on this originally 
18-member (but for most of the past 
two years a 17-member) Council, as 
scientists we would be in the minority 
in our belief of the good to be gained 
through these and other areas of 
biomedical research. We were also 
aware that some others on the Council 
had strong opposing views. Thus, it 
was only with the assurances of the 
Council chairman, Leon Kass of the 
University of Chicago, and of the 
President of the United States himself 
that we were persuaded that our 
voices would be heard and integrated 
into the statements of the Council. 
Furthermore, we felt, and continue 
to feel, that bioethical issues are 
important not only to all biologists, 
but also to society at large, and thus 
especially worthy of engaging debate 
and discussion.
Two recently issued reports of 
the Council, “Beyond Therapy: 
Biotechnology and the Pursuit of 
Happiness” (http:⁄⁄bioethics.gov/
reports/beyondtherapy/index.html) 
and “Monitoring Stem Cell Research” 
(http:⁄⁄bioethics.gov/reports/
stemcell/index.html), are therefore of 
deep concern to us. We discuss them in 
turn below.
Concerns about the “Beyond 
Therapy” Report
The “Beyond Therapy” report deals 
with issues of direct concern for every 
thoughtful person. However, in the 
interests of setting straight the record 
of our views, as Council members 
and scientists, on the content of this 
report and for a proper assessment of 
the scientiﬁ  c content of the “Beyond 
Therapy” report, we feel it is important 
to point out aspects of the report for 
which we had requested revisions and 
for which those requests were declined.
In the discussions of preimplantation 
genetic diagnosis, the specter of 
designer babies is raised by implying 
that selecting embryos for intelligence 
and other traits, such as temperament 
is a possibility. Scientiﬁ  cally, this simply 
is highly unlikely and indeed may not 
even be feasible. While such scientiﬁ  c 
unlikelihood is mentioned in passing in 
the report, it is easy to take away from 
the report the feeling that such genetic 
manipulation will happen and is even 
imminent.
The report also claims that “the 
underlying impulse driving age-
retardation research is, at least 
implicitly, limitless, the equivalent of a 
desire for immortality.” Furthermore, 
the title of Chapter 4 of the report, 
“Ageless Bodies,” implies that 
immortality is the goal of this research, 
despite all reliable scientiﬁ  c evidence 
to the contrary. Such a title is not 
consistent with the knowledge, stated in 
that chapter, that there is no scientiﬁ  c 
basis for immortality and implies that, 
by seeking to maintain and extend 
“youth,” research into aging, including 
stem cell research, is predominantly to 
serve vanity. Also, without presenting 
scientiﬁ  c or reliable evidence, the 
report presents the opinion that 
research into prolonging healthy life 
may result in a lifetime obsession with 
immortality. Hence, this chapter in 
the report falls short of explaining the 
serious challenge of preventing and 
curing age-related disease to extend 
health—very different from attempting 
immortality.
The same chapter offers a 
sensational quote from a researcher 
that “the real goal [of aging research] 
is to keep people alive forever.” The 
request that quotes from researchers 
more representative of the biomedical 
research community also be included 
was declined. This leads to a misleading 
misrepresentation of the motivation 
of reputable researchers in the ﬁ  eld of 
aging.
In suggesting that slowing biological 
aging may increase the disjunction 
between “social aging” (the age at 
which children are exposed to “adult” 
images and concepts) and “biological 
aging” (expected lifespan), only 
one view, a conservative one, of the 
supposed “best” way to raise children 
is presented. The report also suggests, 
with no clear reasoning behind it, that 
longer lives will somehow undermine 
human determination to contribute 
as much as one can during a lifetime. 
Despite requests for inclusion of 
material that would allow for a 
balanced treatment of these topics, 
the report minimized discussion of 
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potential positive aspects of slowing 
biological aging, such as prolonged 
good health.
Finally, the report repeatedly 
emphasizes a “profound and 
mysterious” link between longevity and 
fertility, thereby leaving the reader with 
the distinct but erroneous impression 
that anything done to extend healthy 
life will be traded for decreased fertility, 
despite the fact that current scientiﬁ  c 
literature, which was made available for 
inclusion in the report, shows a lack of 
any necessary mechanistic linkage of the 
two.
Concerns about the “Monitoring 
Stem Cell Research” Report
With respect to the “Monitoring 
Stem Cell Research” report, we feel 
that some facts that would help the 
public and scientists better assess 
the content of the report were not 
brought out clearly or were omitted 
entirely. First, from the published 
scientiﬁ  c literature in peer-reviewed 
journals on stem cells, a major message 
can be distilled: namely, the vast 
difference that currently exists in our 
understanding of, and the potential 
utility of, embryonic versus adult 
stem cells as sources of material for 
research and clinical purposes. In brief, 
human stem cells have been isolated 
from a variety of embryonic, fetal, 
and adult tissue sources. However, 
enormous differences exist in purity, 
properties, data reproducibility, 
and understanding of cells from 
these different sources. Much of our 
ignorance is related to the relative 
paucity of funding for research using 
embryonic stem cells.
Years of rigorous and careful 
research in animal models have 
documented that embryonic stem 
cells have great utility for scientiﬁ  c 
studies. This work has also rigorously 
and reproducibly established the great 
plasticity of these cells and supports 
the opinion that human embryonic 
stem cells possess the greatest broadest 
potential and promise for clinical 
applications. As well as therapeutic 
uses, important potential applications 
include studies of embryonic stem cells 
bearing complex genotypes susceptible 
to poorly understood common human 
diseases and testing and screening drug 
efﬁ  cacy.
The report does not make clear that 
the best-characterized adult stem cells 
are hematopoietic stem cells. Currently, 
major difﬁ  culties and inadequate 
understanding exist with most other 
types of adult stem cells reported to 
date. In addition, many experiments 
suggesting that adult stem cells have 
broad plasticity may be incorrectly 
interpreted owing to an error caused by 
an experimental artifact of cell fusion 
present in some unknown proportion 
of the experiments. Research on 
some of the reported adult stem cell 
preparations may conceivably in the 
future demonstrate that they, too, like 
hematopoietic stem cells, can also 
be prospectively identiﬁ  ed, “single 
cell cloned,” expanded considerably 
by growth in vitro with retention of 
normal chromosome structure and 
number, and preserved by freezing 
and storage at low temperatures. But 
it should be strongly cautioned that 
this has not been done for most adult 
stem cell preparations, and, even if 
possible, it is not clear that any of the 
just-mentioned procedures will be 
accomplished in the near future, owing 
to the technically very demanding 
nature of such experiments.
We feel it is important to emphasize 
a point that the report mentioned, 
that the reported isolation and 
properties of multipotent adult 
progenitor cells (MAPCs) must be 
reproduced in additional laboratories 
for any reliable interpretation of the 
results reported with these cells. After 
considerable effort, this has still not 
been achieved. Thus, in the reported 
results, the possible signiﬁ  cance of 
the reported isolation and properties 
of human MAPCs is left unclear, as 
is their potential as a source of stem 
cells for clinical purposes. Hence, a 
strong overall caution is that many 
of the reports on the properties 
of cells differentiated from adult 
stem cell preparations are to date 
preliminary and incomplete. If results 
with any isolated and characterized 
adult stem cells are validated, it will 
then be very important to compare 
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their properties—and those of any 
more differentiated cells that can 
be derived from them—with other 
stem cell sources, such as the well-
characterized hematopoietic stem cells, 
and with human embryonic stem cell 
preparations. 
Two major considerations argue 
strongly for non-commercial, federal, 
peer-reviewed funding to be made 
available for this work. The ﬁ  rst is 
the sustained effort this work will 
require. The second is the importance 
of reliable and unbiased design of 
experiments and of open, public 
availability of the complete ﬁ  ndings.
Reasons for Our Concern
In being concerned about the 
content of these reports, neither of 
which makes any recommendations 
for legislative or policy actions, are 
we worrying too much? We think not. 
Indeed, already, sadly as a result of the 
way the sections on aging research in 
the report were written, the myth that 
longevity has an inevitable tradeoff of 
diminished fertility is now gaining a 
further foothold: witness the January 
26, 2004, issue of the The New Republic. 
In it, an article about this report of 
the Council falls right into the trap: it 
states, “But changes come with longer 
life. Worms and mice that are altered 
for extended lifespans become sterile, 
or barely reproduce.” The public 
is done a disservice when science is 
presented incompletely; myths are then 
perpetuated. 
This is but one example of the 
dangers that three of the Council 
members who are scientists (the two 
of us along with Michael Gazzaniga of 
Dartmouth College) pointed out, in a 
Commentary within the edition of the 
“Beyond Therapy” report published 
by the Dana Foundation in November 
2003. In that Commentary, we stated 
that “Our concern ...  is that, moving 
forward, the debate carry on with all 
of the scientiﬁ  c evidence—or as much 
as such a widespread public discussion 
can include—and take care not to 
leave an erroneous impression as to 
the nature of the potential problems at 
hand.” We ended the Commentary by 
saying “We urge both good reading and 
critical reading!” (our italics).
These reports had as their premise 
the aim of neutrality in the scientiﬁ  c 
analysis of the issues addressed. But our 
concern is that some of their contents, 
as in the few examples outlined 
above, may have ended up distorting 
the potential of biomedical research 
and the motivation of some of its 
researchers. Continuing discussions will 
form the basis for future decisions on 
these topics; keeping such discussion 
open and balanced is of paramount 
importance.  
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